For almost two years, patients with Fabry's disease have been dealing with severe shortages of the medicine they need — Genzyme's Fabrazyme — as Genzyme deals with manufacturing problems and contamination. A year ago, the patients asked NIH to step in and demand that Genzyme allow other drug companies to make Fabrazyme, a provision known as "march-in" rights that NIH can exercise under certain circumstances according to the Bayh-Dole Act.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.